hotspot -WSS

hotspot

author：entertainment 2025-09-28 02:32:20 - browse：485

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

Wikipedia

hotspot

WSS

FDA clears Verve to begin U.S. study of gene

STAT Summit: Ending the crisis of Black deaths in the U.S.

ASCO: AstraZeneca says CAR

Merck, Daiichi strike cancer drug pact worth up to $22 billion

UnitedHealth, Optum discontinue NaviHealth name

Cord blood banking comes at a high cost to babies

focus

hotspot

entertainment

Jerome Adams on the need for new antivirals for Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Supreme Court strikes down use of affirmative action

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Peter Hotez and the public health issue of online harassment

STAT Summit: The economic case for universal basic health care

The high cost of giving birth even with insurance

ASCO: Palliative care found as helpful given virtually as in person

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

STAT Readout: Friday, Oct. 20 biotech updates

FDA's Pazdur wants cancer trials to range beyond China alone

At ASCO, AstraZeneca reports strong data for breast cancer drug

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

STAT Summit: Meghan O’Rourke on making chronic illness visible

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Wikipedia

hotspot

entertainment

hotspot